The Marked Chart Wire · Health
Biohaven
Biohaven shares phase 1 results for BHV-1530
Biohaven disclosed early trial data for its antibody-drug conjugate BHV-1530. The findings showed that patients with FGFR3-altered cancers experienced shrinkage of tumors and other clinical benefits.
